Advancing Gene Therapies & Enabling Disease Models

A joint conference of the GET-IN & LifeLUNG EU consortia

3 to 5 February, 2027⎮Leuven, Belgium

The rapid evolution of advanced therapy medicinal products (ATMPs) is transforming the therapeutic landscape, offering unprecedented opportunities to address diseases with high unmet medical needs. Across Europe, progress in gene and cell therapies, RNA-based approaches, and engineered tissues is being driven by increasingly integrated efforts spanning basic research, technology development, manufacturing innovation, and clinical translation.

Timeline

03. September 2026

Registration opens (early bird)

06. December 2026

Registration regular fee

24. January 2027

Registration closes

3.-5. February

Conference

Conference venue

KU Leuven University Hall

Naamsestraat 22 | 3000 Leuven

Coordinated by KU Leuven, this joint conference unites the MSCA Doctoral Networks GET-IN and LifeLUNG with the broader Advanced Therapy Medicinal Product (ATMP) community.

Why Attend?

Explore cutting-edge advances: Discover the latest breakthroughs across diverse therapeutic modalities and organ systems, including viral vector technologies and advanced disease models.
Master next-gen bioprocessing: Gain insights into precision engineering workflows that integrate multi-omics profiling, data-driven analytics, and AI-enhanced workflows.
Shape the Future of ATMPs: Join diverse stakeholders to address shared bottlenecks, highlight emerging opportunities, and accelerate the translation of innovative therapies to patients.

By uniting the GET-IN and LifeLUNG consortia within a broader ATMP ecosystem, this meeting catalyzes multi-disciplinary collaborations to strengthen Europe’s leadership in developing, evaluating, and deploying next-generation advanced therapies.

Stakeholder contributions

Designed as a collaborative platform for cross-disciplinary and cross-sector exchange, the conference features insights from:

Academia & research institutions
Biotech & pharmaceutical industry
Clinical research & Medicine
Regulatory science & policy
Technology & platform development

Core conference themes

Sessions will cover the full end-to-end value chain of advanced therapy development:

Discovery & mechanisms: Advancing target identification and mechanistic understanding
Bioprocessing & scale-up: Translating laboratory concepts into scalable manufacturing and quality control
Translation & implementation: Navigating regulatory frameworks and driving clinical adoption